A NEW chemical entity fixed dose combination product has had an Australian Public Assessment Report (AusPAR) posted by the Therapeutic Goods Administration.
Orkambi 200/125 (lumacaftor/ivacaftor) is a cystic fibrosis (CF) treatment from Vertex Pharmaceuticals.
For details see www.tga.gov.au.
THE Therapeutic Goods Administration (TGA) is today launching a public consultation to explore the possibility of expanding the regulation of unapproved medicinal cannabis products, a move welcomed by the Pharmaceutical Society of Australia.
AMCAL has presented a $200,000 donation to charity partner RizeUp Australia at its recent 10th Anniversary Gala Ball.
WESTERN Australia is the latest state to move towards greater access to care from community pharmacists, with WA Minister for Health Meredith Hammat announcing 17 common acute and chronic conditions that will soon be treatable by qualified pharmacists.
Notifications
